We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
For SARS-CoV-2, which causes COVID-19, LumiraDx’s test has a positive agreement of up to 95.5 percent and a negative agreement of up to 99.2 percent with RT-PCR tests, based on clinical data collected up to 12 days after symptom onset. Read More
The system’s biggest benefit is the “ability to assess the function of the organ on the device prior to committing to the transplant,” said the principal investigator for the trial that supported the FDA approval. Read More
The system is the latest in the company’s Stratum line, which now includes almost 90 products to treat deformities and fractures in the foot and ankle. Read More
The company will begin marketing the technology in the U.S. in the coming weeks on a limited basis and is planning a national rollout by the end of March. Read More
The FDA grants breakthrough device status to novel medical devices that have the potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Read More
The first test available on BD’s newly CE-marked MX instrument is the BD CTGCTV2, which detects the three most prevalent nonviral sexually transmitted infections. Read More